Tumor Type

Australia
Canada
(partner)
Pancreatic Cancer - Ductal adenocarcinoma
Australian Pancreatic Cancer Genome Initiative  HTML
Funding Organizations
Research Organizations
Research Activities
Publication Policy

1:   QCMG Project Specific Moratorium HTML 
2:   ICGC Goals, Structure, Policies and Guidelines Section E.3 - Publication Policy HTML 
3:   Template Letters to Facilitate Communications HTML 
to ensure appropriate dialogue between data users and generators and for authors to contact ICGC members and editors
Clinic & Pathology

Australia: Australian Pancreatic Cancer Genome Initiative
Garvan Institute of Medical Research
Italy: University of Verona
United States: Johns Hopkins University
University of California, San Francisco
Sequencing & Analysis

Australia: Institute for Molecular Bioscience
Complementary Studies

Australia: Garvan Institute of Medical Research
Institute for Molecular Bioscience
Data Storage, Analysis & Management

Australia: Garvan Institute of Medical Research
Institute for Molecular Bioscience
Project Summary

The primary aims of the Australian Pancreatic Cancer Genome Initiative (APGI) are to deeply sequence tumor and normal gDNA, survey global gene expression (by RNAseq approaches), and determine genome wide patterns of methylation of ~375 pancreatic cancer patients.

The goal is to use the best clinical material available, with well-characterised and accurately annotated clinico-pathological, treatment and outcome data acquired prospectively.

Principal Investigators

Institute for Molecular Bioscience
• Sean M. Grimmond (overall lead)
• David Miller
• Conrad Leonard
• Nicola Waddell
• Peter Wilson
• John V. Pearson
• Karin Kassahn

Garvan Institute of Medical Research
• Andrew V. Biankin (pancreatic cancer lead)
• Amber Johns
• Anthony Gill
• Nik Zeps
APGI Collaborators

Johns Hopkins University
• Ralph H. Hruban
• James R. Eshleman
• Anirban Maitra
• Christine Iacobuzio-Donahue

University of Verona
• Aldo Scarpa
• Claudio Bassi
• Rita Lawlor

Lead Jurisdiction